AR045416A1 - Coadyuvante de linfocitos humanos para vacunas - Google Patents

Coadyuvante de linfocitos humanos para vacunas

Info

Publication number
AR045416A1
AR045416A1 ARP040100565A ARP040100565A AR045416A1 AR 045416 A1 AR045416 A1 AR 045416A1 AR P040100565 A ARP040100565 A AR P040100565A AR P040100565 A ARP040100565 A AR P040100565A AR 045416 A1 AR045416 A1 AR 045416A1
Authority
AR
Argentina
Prior art keywords
vaccines
coadyuvant
adjuvant
human lymphocyte
derived
Prior art date
Application number
ARP040100565A
Other languages
English (en)
Original Assignee
Hasumi Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34102590&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR045416(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hasumi Llc filed Critical Hasumi Llc
Publication of AR045416A1 publication Critical patent/AR045416A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Coadyuvante derivado de linfocitos humanos. El coadyuvante puede usarse en combinación con vacunas tradicionales o inmunoterapia para el cáncer, para mejorar la respuesta del sistema inmune del paciente ante la vacuna o ante otro agente inmunoterapéutico. El coadyuvante deriva del sobrenadante recolectado de linfocitos cultivados activados.
ARP040100565A 2003-02-21 2004-02-23 Coadyuvante de linfocitos humanos para vacunas AR045416A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44952803P 2003-02-21 2003-02-21

Publications (1)

Publication Number Publication Date
AR045416A1 true AR045416A1 (es) 2005-10-26

Family

ID=34102590

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100565A AR045416A1 (es) 2003-02-21 2004-02-23 Coadyuvante de linfocitos humanos para vacunas

Country Status (13)

Country Link
US (2) US7745157B2 (es)
EP (1) EP1599170B1 (es)
JP (1) JP5010280B2 (es)
KR (1) KR20060023519A (es)
CN (1) CN1787835A (es)
AR (1) AR045416A1 (es)
AU (1) AU2004258799A1 (es)
BR (1) BRPI0407727A (es)
CA (1) CA2516783A1 (es)
CL (1) CL2004000340A1 (es)
MX (1) MXPA05008936A (es)
RU (1) RU2341289C2 (es)
WO (1) WO2005009397A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7818101B2 (en) * 2005-12-30 2010-10-19 Canadian National Railway Company System and method for computing rail car switching solutions in a switchyard using an iterative method
CN101426514A (zh) * 2006-04-25 2009-05-06 英特塞尔股份公司 Hcv疫苗
JP2010508364A (ja) * 2006-10-31 2010-03-18 ハスミ インターナショナル リサーチ ファウンデイション 樹状細胞腫瘍注射治療及び関連するワクチン
US9907819B2 (en) 2012-06-27 2018-03-06 Kenichiro Hasumi Therapy and methods of introducing immature dendritic cells and/or cytotoxic T lymphocyte and anti-TNF antibody for treatment of tumors
US20140205609A1 (en) * 2013-01-24 2014-07-24 Fred T. Valentine Methods for inducing systemic immune responses to cancer
CN104212760B (zh) * 2013-05-29 2017-08-08 中国科学院上海生命科学研究院 肌肉干细胞体外培养方法及其应用
WO2015077532A1 (en) * 2013-11-21 2015-05-28 Hasumi International Research Foundation Therapy and methods of introducing immature dendritic cells and/or cytotoxic t lymphocyte and anti-tnf antibody for treatment of tumors
US20170303530A1 (en) * 2014-11-14 2017-10-26 Japanese Red Cross Society Method and solution for cryopreservation of umbilical cord blood and peripheral blood

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1980183A (en) * 1982-10-01 1984-04-05 Bio-Com Inc. Compositions for inducing immunosuppression or immunoregulation of the immune response to an antigen
DE69333433T2 (de) 1992-04-01 2004-12-02 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
US5747024A (en) 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
US8333996B2 (en) 1995-05-19 2012-12-18 Etex Corporation Calcium phosphate delivery vehicle and adjuvant
GB9521568D0 (en) 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
US20020142352A1 (en) 1999-03-04 2002-10-03 Heska Corporation Novel ectoparasite salvia proteins and apparatus to collect such proteins
US6063610A (en) 1996-11-12 2000-05-16 Heska Corporation Carboxylesterase nucleic acid molecules, proteins and uses thereof
WO1999061618A2 (en) 1998-05-29 1999-12-02 Heska Corporation Canine and feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
US6432679B1 (en) 1998-06-12 2002-08-13 Henry M. Jackson Foundation For The Advancement Of Military Medicine Enhancement of B cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and EBV Gp350/220
US6270758B1 (en) 1998-10-08 2001-08-07 Duke University Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
US6573372B2 (en) 1999-01-07 2003-06-03 Heska Corporation Feline immunoglobulin E molecules and compositions there of
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6416977B1 (en) 1999-04-09 2002-07-09 Heska Corporation Flea chitinase nucleic acid molecules and uses thereof
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
US20020094323A1 (en) 2000-10-12 2002-07-18 Kristoffer Hellstrand Methods and compositions for promoting the maturation of monocytes
ES2338305T3 (es) 2001-09-28 2010-05-06 Purdue Research Foundation Metodo de tratamiento que utiliza conjugados ligando-inmunogeno.
AU2002363322A1 (en) 2001-10-26 2003-05-19 Large Scale Biology Corporation Endothelial cell derived hemotopoietic growth factor
US7736652B2 (en) 2002-03-21 2010-06-15 The Regents Of The University Of California Antibody fusion proteins: effective adjuvants of protein vaccination
CN1662251B (zh) 2002-04-19 2012-10-10 恩多塞特公司 佐剂增强的免疫应用

Also Published As

Publication number Publication date
RU2341289C2 (ru) 2008-12-20
MXPA05008936A (es) 2006-05-25
CL2004000340A1 (es) 2005-05-20
CA2516783A1 (en) 2005-02-03
WO2005009397A2 (en) 2005-02-03
JP2007531703A (ja) 2007-11-08
US8088397B2 (en) 2012-01-03
KR20060023519A (ko) 2006-03-14
RU2005129134A (ru) 2006-03-27
AU2004258799A1 (en) 2005-02-03
EP1599170A2 (en) 2005-11-30
EP1599170A4 (en) 2007-05-09
BRPI0407727A (pt) 2006-05-02
US20100266534A1 (en) 2010-10-21
WO2005009397A3 (en) 2005-11-17
CN1787835A (zh) 2006-06-14
EP1599170B1 (en) 2013-01-16
US20040241183A1 (en) 2004-12-02
JP5010280B2 (ja) 2012-08-29
US7745157B2 (en) 2010-06-29

Similar Documents

Publication Publication Date Title
BRPI0010612B8 (pt) vacinas
AR022965A1 (es) Vacuna
MX2018010586A (es) Nanovacuna de activacion de "sting" para inmunoterapia.
WO2009060281A3 (en) Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
EP1728863A3 (en) C-class oligonucleotide analogs with enhanced immunostimulatory potency
DK1225870T3 (da) Sammensætning og fremgangsmåde til cancerantigenimmunterapi
WO2008112344A3 (en) Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
TW200719910A (en) C. perfringens alpha toxoid vaccine
BRPI0518793A2 (pt) mÉtodos para tratar, controlar ou prevenir uma doenÇa ou distérbio de imunodeficiÊncia, e para melhorar a resposta imune a um imunogene, e, composiÇço farmacÊutica
ATE499113T1 (de) Influenzavirus-impfstoffzusammensetzung
BRPI0510430A (pt) composições e métodos para vacinação mucosal
WO2006071983A3 (en) Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
BR0314373A (pt) Produto imunogênico estável para a indução de anticorpos contra uma ou várias proteìnas antigênicas em um indivìduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico
BR0208675A (pt) Combinação imunoterapêutica para a imunoterapaia de tumores que superexpressam gangliosìdeos, uso da mesma e método para controlar o crescimento e/ou a proliferação de células tumorais que superexpressam gangliosìdeos
AR045416A1 (es) Coadyuvante de linfocitos humanos para vacunas
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
DE60136928D1 (de) Verwendung von pflanzen-öl-körper in impfstoffverabreichungsysteme
AR039982A1 (es) Composicion vacunal contra las alergias, metodo para su obtencion y empleo en el tratamiento de las mismas
MX371087B (es) Vacunas sintéticas contra el serotipo 2 de streptococcus pneumoniae.
HUP0204216A2 (en) A new use of antibodies as vaccines
WO2004027036A3 (en) Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine
BR0011478A (pt) Composição de combinação imunológica, métodos de induzir uma resposta imunológica em um animal, e de imunizar um hospedeiro contra infecção pneumocócica, e, composição imunogênica para administração intranasal
MX2021015155A (es) Polisacaridos de ramnosa.
DK1742656T3 (da) Hidtil ukendt jordnøddeskindekstrakt som adjuvansvaccine
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form

Legal Events

Date Code Title Description
FB Suspension of granting procedure